Professor of Regenerative Medicine for Diabetes and Honorary Consultant Physician
Newcastle University
Morpeth, England, United Kingdom
Following PhD completion as an MRC Clinical Research Training Fellow with Kevin Docherty exploring gene and cell replacement therapy for diabetes, a Glaxo-Smith-Kline Senior Fellowship enabled Shaw to move to Newcastle and join the world-acclaimed diabetes team there.
In addition to setting up a translational research laboratory he has developed a regional complex Type 1 diabetes service focused on specialist hypoglycaemia management incorporating pump therapy and continuous glucose monitoring. He has established a supra-regional islet transplant service truly integrated with the solid organ pancreas transplant programme.
He is Chief Investigator for the multicentre Diabetes UK-funded HypoCOMPaSS RCT comparing optimised insulin analogue with pump therapy and conventional with continuous glucose monitoring in Type 1 diabetes complicated by impaired awareness of hypoglycaemia. He led the successful United Kingdom Islet Transplant Consortium bid for dedicated NHS funding of this intervention as an established clinical procedure in 2008. This underpinned a further multicentre Diabetes UK grant to prospectively evaluate biomedical / psychosocial outcomes in all UK islet recipients; and enabled participation in the only international RCT in islet transplantation, evaluating the potential of a novel anti-inflammatory agent to maximise engrafted islet mass post-transplantation. He is clinical lead for a burgeoning exercise in Type 1 diabetes research programme in collaboration with Dr Dan West.
His laboratory group is exploring mechanisms underlying loss of beta-cell mass and function in diabetes in addition to further innovations in islet transplantation. As Director of the Transplant Regenerative Medicine Laboratories, he has established the Newcastle Islet Isolation and Innovation Hub providing research tissue processing and human islet isolation. Potentially reversible beta-cell dedifferentiation as a common mechanism underlying beta-cell dysfunction in Type 1, Type 2 and cystic fibrosis-related diabetes in addition to post-transplantation is becoming a major focus, facilitated by recent funding from the CF Trust enabling him to establish an international collaborative Strategic Research Centre consortium.
He is Newcastle lead for an MRC-funded initiative to extend the Quality and Safety in Organ Donation Biobank led by Prof Rutger Ploeg in Oxford, to include pancreas, islets hearts and lungs. Through the Newcastle MRC Molecular Pathology Node, this will provide a unique platform for molecular phenotyping across a range of organs linked to clinical data and a circulating biomarker proteomic core.
He is clinical lead for the Translation and Clinical Research Institute Regenerative Medicine, Stem Cells and Transplantation Theme. He is Newcastle University Chief Investigator for the Northern Alliance Advanced Therapies Treatment Centre, one of three Innovate UK-funded centres with the goal of accelerating trials and clinical adoption of cell and gene therapies.
He previously co-edited the international textbook ‘Islet transplantation and beta-cell replacement therapy’ with James Shapiro and is editor for the Type 1 diabetes section of the Oxford Textbook of Endocrinology and Diabetes.
Disclosure information not submitted.
Wednesday, September 21, 2022
2:20 PM – 3:20 PM CT
